Pfizer Reports real-world evidence Data for Tofersen in Cystic fibrosis

Pfizer today announced real-world evidence results for tofersen in patients with cystic fibrosis. The study demonstrated that tofersen reduces exacerbation rates compared to standard of care or placebo. These results provide important insights into the treatment of cystic fibrosis and support the continued development of tofersen in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.